Abstract: The invention relates to a method for the solubilization, by means of ion exchanger resins, of otherwise insoluble protein expressed by cultivated cells.

Abstract: A process for isolating and purifying GM-CSF produced from recombinant sources. The process provides for the isolation and purifying of recombinant GM-CSF produced in E. coli.

Abstract: Thrombin-binding substances are obtained by fractionating human urine by ion-exchange chromatography, affinity chromatography using a thrombin-bound carrier, immune adsorption column chromatography, gel filtration, and/or molecular-weight fractionation. One of the substances has a molecular weight of 46,500.+-.6,000 in reduced condition and 39,000.+-.10,000 in unreduced condition by SDS PAGE and an isoelectric point at pH 5.0-5.3, while the other has a molecular weight of 40,000.+-.8,000 in reduced condition and 31,000.+-.10,000 in unreduced condition by SDS PAGE and an isoelectric point at pH 4.9-5.7. They have strong affinity to thrombin. They are capable of promoting the thrombin catalyzed activation of protein C and prolong clotting time. They are stable to denaturing agents (urea and sodium dodecylsulfate).

Abstract: Metal chelate resins whose complexed nitrilotriacetic acid residues are bound to a carrier matrix via a spacer and which are suitable for metal chelate chromatography of proteins, especially those which contain neighboring histidines.

Abstract: A chromatography material comprises a solid support on which is fixed, as a ligan, desialyled gycolprotein selected from desialyled fetuin and desialyled haptoglobin. This material is used to purify protein antigens of bacteria of the Bordetella genus.

Abstract: A novel cell scattering factor, i.e., tumor egress factor (hereinafter "egressin") isolated from a clone derived from a human metastatic melanoma (M3827) which possesses a loose colony morphology and from a human monocytic cell line (U937) and processes for producing the same. Egressin is useful for the production of immunological reagents for the detection and treatment of metastatic lesions, for aiding in the transport of drugs across the blood-brain barrier, and for aiding in the control of the inflammatory response.

Abstract: A device for the determination of amino acid sequence of a polypeptide comprises two new features offering great advantages in the cost and efficiency of operation of amino acid sequencers. The sequencer is provided with the capability for the bidirectional flow of sequencing reagents and contains a sample chamber having a bicompositional adsorbent for the polypeptide.

Abstract: The present invention relates to a novel glycoprotein, extracted from the seeds of Trichosanthes kirilowii, called: trichokirin, as well as to its modified derivatives containing a free or blocked SH group.It relates to a process for its preparation, to its use and to pharmaceutical compositions in which it is present.

Abstract: Active recombinant human IL-4 is purified from a crude cell culture medium of a CHO-cell lines mutant by subjecting said crude solution to two sequentialcation exchange chromatographies at pH 7.2 and 0.12M sodium chloride, selective chromatography on a cobalt-chelating agarose column at pH 7.2 in a buffer containing a high concentration of sodium chloride, i.e., about 0.5M sodium chloride, further treated by concentration (diafiltration) up to 20 mg/mL and size exclusion gel chromatography using a citrate buffer at pH 4.5.

Abstract: A substantially pure species of avian Interleukin-2 has a molecular weight of about 30 kda. as determined by SDS-polyacrylamide gel electrophoresis. The compound is obtained from avian lymphocytes. It is produced by collecting lymphocytes from an avian donor, growing the lymphocytes in a medium containing a T cell mitogenic agent, and recovering the compound from the medium.

Abstract: Disclosed are monoclonal antibodies which react with human tumor cells, particularly metastatic human tumor cells, but not with normal human tissues tested. The monoclonal antibodies are prepared against a 580 kilodalton glycoprotein antigen, designated gp580, which is isolated from either rat or human tumor cells. Methods for isolating the glycoprotein antigen are disclosed as well. Moreover, techniques are disclosed for utilizing these antibodies both in the detection and in the prevention of human tumor lesions.

Abstract: A method of separating charged molecules having different numbers of charges thereon includes the step of passing the molecules to be separated through ion-exchange material such as an ion-exchange chromatograpy column in normal manner so that molecules to be separated bind to the ion-exchange material. Displacer molecules are then passed through the ion-exchange column to selectively release certain of the molecules to be separated from the ion-exchange material, while others of the molecules to be separated remain bound to the material.

Abstract: A process is provided for the purification of a proteinaceous physiologically active substance having antitumor activity, which is induced by administering to a rabbit at least one substance having a capacity for stimulating reticuloendothelial system and then injecting endotroxin from a Gram-negative bacterium into the rabbit. The process comprises contacting a crude solution of said proteinaceous physiologically active substance with a basic anion exchanger to have said physiologically active substance adsorbed on the anion exchanger, eluting the adsorbed physiologically active substance, and subjecting the eluate containing said physiologically active substance to gel filtration with a gel suitable for separation of a substance with a molecular weight in the range of 30,000 to 70,000. The purified preparation of said physiologically active substance thus obtained may be used as an antitumore agent for the treatment of malignant tumors.

Abstract: These resins derived from a crosslinked styrene (co)-polymer, or from a crosslinked dextran, comprise a (co)-polymer chain which is substituted with one or more groups, which may be identical or different, belonging to the following categories: --Z--A.sub.1 ; --Z--A.sub.2 ; --Z--A.sub.1 --Z'--A.sub.2 ; --Z--A.sub.1 --A.sub.3 --A.sub.2 ; --Z--A.sub.1 --A.sub.4, where Z=spacer chain, Z'=linking chain, A.sub.1 =phosphate residue, A.sub.2 =residue of purine or pyrimidine base, A.sub.3 =sugar residue and A.sub.4 =residue of a molecule participating in the polar structure of various phospholipids. These resins are applicable for the analysis and purification of molecules of biological origin, in particular as a stationary phase in ion-exchange and affinity chromatography, especially for carrying out the fractionation of protein mixtures.

Abstract: Disclosed are chromatography methods and matrix geometries which permit high resolution, high productivity separation of mixtures of solutes, particularly biological materials. The method involves passing fluids through specially designed chromatography matrices at high flow rates. The matrices define first and second interconnected sets of pores and a high surface area for solute interaction in fluid communication with the members of the second set of pores. The first and second sets of pores are embodied, for example, as the interstices among particles and throughpores within the particles. The pores are dimensioned such that, at achievable high fluid flow rates, convective flow occurs in both pore sets, and the convective flow rate exceeds the rate of solute diffusion in the second pore set. This approach couples convective and diffusive mass transport to and from the active surface and permits increases in fluid velocity without the normally expected bandspreading.

Abstract: The present invention is based on the discovery that amyotrophic lateral sclerosis (ALS), Parkinson disease and Alzheimer disease are due to lack of a disorder-specific neurotrophic hormone or factor. Diagnosis is accomplished by assaying factors specific for a particular neuronal network or system; for example, dopamine neutotrophic hormones from striatum or caudate-putamen in the nigrostriatal dopaminergic neural system are used to diagnose and treat parkinsonism. With tissue culture, the presence or absence of spacific neurotrophic factos can be assessed in ALS, parkinsonism, and Alzheimer disease. If there is a deficiency, extracted and purified neurotrophic factors specific to the particular neuronal network or system can be injected into a patient having ALS, Alzheimer disease or parkinsonism for treatment of the disease.

Abstract: A process is described for the purification of plasminogen activator (PA), wherein a solution containing such as plasminogen activator is brought into contact with a carrier-bound polysulfate of a saccharide or sulfated sugar, the liquid is removed, and the PA bound by this material is eluted.

Abstract: A method for separating immunoglobulin G subclasses, which comprises separating immunoglobulin G subclasses by liquid chromatography by using as the solid phase a porous gel having an exclusion limit molecular weight larger than the molecular weight of immunoglobulin G, as calculated as protein, and a buffer solution having an ionic strength of from 0.1 to 2.0M.

Abstract: A gel contactor receives a fluid media produced in a bio-reactor and containing a product to be extracted, cells and other particles. The gel contactor has a cylindrical container with a cylindrical filter mounted inside the container. A freely rotatable wiper blade sweeps the upstream side of the filter in a closely spaced relationship. The container holds a supply of beads of an absorptive chromatography media such as an ion-exchange or affinity type gel, that selectively bond to the product. An orbital drive causes the blade, process fluid and gel to revolve. The rotation of the blade depolarizes the filter and circulates the process fluid process fluid and gel within the container so that they are well mixed, with substantially no dead spots. After mixing and filtration an elution buffer solution strips the product from the gel. There are no rotary seals connecting to the container.

Abstract: A ciliary neurotrophic factor (CNTF), particularly sciatic nerve CNTF (SN-CNFT) is claimed. The SN-CNTF described herein is a single protein species and has a specific activity that increased to greater than 25,000-fold from crude extract. The purification is carried out by lowering the pH of the crude nerve extract preparation to form a precipitate which is removed and discarded; raising the pH to about 6.3 followed by ammonium sulfate fractionation; chromatofocusing a solution containing a second precipitate obtained from the 30% to 60% ammonium sulfate containing solution; subjecting the fractions obtained by chromatofocusing to sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE); and performing reversed-phase high-performance liquid chromatography (HPLC) on the SDS-PAGE eluate.Amino acid data for this SN-CNTF is also provided. In addition, methods for using this data for providing SN-CNTF probes and for screening cDNA and genomic libraries are also provided.

Abstract: A method for the preparation of a protein in a physiologically active or native form, which method includesproviding a source of protein in a solubilized form,and a cationic exchange medium;contacting the source of protein and cationic exchange medium; andrecovering the protein in a physiologically active form.

Abstract: The gene encoding protease nexin I (PN-I) is cloned and expressed to provide practical quantities of PN-1 for diagnostic and therapeutic use. PN-I is a serine protease inhibitor useful in controlling conditions mediated by proteolytic activity.

Abstract: A protein called PA binding protein has been isolated which binds specifically and reversibly to tissue plasminogen activator. The protein is characterized by a molecular mass of about 100,000 daltons, and electrophoretic mobility in agarose at pH 8.6 equal to that of plasma .beta.-globulins and an isoelectric point of 6.5 to 7.0. The protein is thermostable up to at least 56.degree. C. and is cleared from the circulation with a half life on the order of days.

Abstract: The present invention encompasses a method for removing proteins from a solution containing polynucleotides and proteins comprising filtering the solution through a nitrocellulose membrane at neutral or basic pH.

Abstract: A process for measuring the amount of stable-type glycated hemoglobin in a sample using high performance liquid chromatography, comprising heating a sample diluted with a hemolysis agent containing a reagent for the removal of unstable-type glycated hemoglobin to achieve the removal of the unstable-type glycated hemoglobin, and analyzing the sample by high performance liquid chromatography.

Abstract: A method is provided for recovering a purified animal growth hormone or a polypeptide analog thereof having substantially the same amino acid sequence as, and the biological activity of, the corresponding naturally-occurring animal growth hormone from a bacterial cell in which the animal growth hormone or polypeptide analog has been produced by means of expression of a plasmid encoding the hormone or polypeptide analog which comprises: (a) disrupting the cell wall of the bacterial cell in a buffered neutral pH solution so as to produce a lysate containing precipitated hormone or polypeptide analog; (b) recovering the resulting precipitated hormone or polypeptide analog; (c) suspending the precipitated hormone or polypeptide analog so recovered in distilled water; (d) treating the resulting precipitate-containing suspension with a sodium hydroxide solution having an alkaline pH of about 11.

Abstract: A method for the recovery of proteins in a solubilized form from host cells including providing a source of host cells incorporating a synthesized or expressed protein; providing a source of at least one cationic surfactant; and treating the host cells with at least one cationic surfactant, in an amount sufficient to effect solubilization of the proteins.

Abstract: A process for the purification of tissue protein PP4 which can be obtained from placenta is described.This process makes use of the property of binding to saccharide polysulfates or to sulfated sugars in the presence of calcium ions.

Abstract: Purified cytotoxic proteins for use within therapeutic compositions are disclosed. The proteins inhibit protein synthesis in vitro, exhibit abortifacient activity in mice, and contain proline residues with equivalent positions at residue 43 and residue 46 in ricin A-chain. A method for preparing such a cytotoxic protein from the tissue of Trichosanthes kirilowii is also disclosed. The proteins may also be used within a method for inhibiting protein synthesis in selected cells.

Abstract: Purified glomerular proteoglycans are used as a basis for a diagnostic test for glomerulonephritis in humans involving an immunological reaction between the purified proteoglycans and patient area. A new method for purification of glomeruli proteoglycan antigens is described using guanidine extraction.

Abstract: Reactivation of cysteine-containing protein in a process, in which a reduced and denatured cysteine-containing protein such as salmon growth hormone I or eel growth hormone I can be efficiently reactivated.

Abstract: A chromatography material comprises a solid support on which is fixed, as a ligand, desialyled gycolprotein selected from desialyled fetuin and desialyled haptoglobin. This material is used to purify protein antigens of bacteria of the Bordetella genus.

Abstract: Protein A is selectively isolated from an antibody--Protein A mixture by exposing the mixture to an anion exchange material under conditions sufficient to adsorb both components and then sequentially eluting the antibodies and protein A under conditions of increasing ionic strength. Resulting antibody preparations have less than about 15 ng of Protein A per mg of antibody.

Abstract: The recovery of vitamin K-dependent proteins produced by transformed microorganisms can be effected from the cell culture medium utilizing the changes in the protein which occur in the presence of divalent cations. The present process uses divalent cations to alter the binding affinity of the proteins and thereby selectively elute the proteins away from contaminants in the culture medium using standard chromatography.

Abstract: A method of purifying a recombinant protein from a solution, such as tissue culture fluid, containing gylcoproteins. The affinity of lectins for specific glycoproteins is assessed and used to select a particular lectin specific for the contaminating glycoprotein(s). A sugar buffer such as alpha methyl mannoside prevents binding of the recombinant protein. The preferred lectin is lentil lectin, for use in separating recombinant Factor VIII from tissue culture fluid contaminated with rodent protein from the cell line used to produce the recombinant Factor VIII.

Abstract: A method for allowing biological macromolecules contained in a solution to be separated by selective absorption comprising supplying with a solution each stage (3, 4) of a column containing a selective chromatographic resin specific to the macromolecules to be separated, so as to fluidize the beds of resin at each stage, each stage being provided at its base with a perforated distribution system (5) characterized by a percentage of open sections between 0.2% and 10%, a mean diameter of the said open sections greater than approximately 300 microns and between 2G.sub.m and 20G.sub.m, where G.sub.m is the mean granulometry of the resin.

Abstract: A method for the renaturation of unfolded proteins comprises reversibly immobilizing the denatured protein on a solid phase and inducing folding of the immobilized protein by progressively reducing with time the concentration of a denaturing agent in the solvent in contact with the solid phase. The refolded protein is recovered from the solid phase in native form. The proteins can be folded and recovered in high yield in a small volume of buffer.

Abstract: This invention relates to processes for producing uromodulin, a glycoprotein having a molecular weight of 85 kilo daltons. This glycoprotein, which is isolated from crude urine, as well as its carbohydrate derivatives, are useful as immunosuppressive agents or anti-inflammatory agents.

Abstract: Novel Fc receptors, denoted type VI, are disclosed as reacting with rat immunoglobulins with a reasonable affinity. The type VI receptors are isolated from Streptococcus zooepidemicus strain s212 (ATCC 53698) and Streptococcus zooepidemicus strain RSS-212 (ATCC 53697) culture supernatants. These receptors, or the microorganisms which produce them, are useful in immunoassays.

Abstract: A reagent comprising a fraction obtained from plasma of an insect such as silkworm larvae and capable of reacting specifically with .beta.-1,3-glucan or peptidoglycan can be used for determining .beta.-1,3-glucan or peptidoglycan.

Abstract: A process for the preparation of a spatial form, which has biological activity, of a protein from a biologically inactive spatial form is described and comprises the protein being dissolved with the addition of a denaturing agent and thus converted into the random coil form, and the solution being allowed to pass through a material which has molecular sieve properties and contains a liquid medium in which the protein can assume a spatial form which has biological activity, and this material having molecular sieve properties being selected so that the molecules of the denaturing agent can penetrate, but the protein molecules canot. It is possible by centrifugation, blowing or sucking out to remove the medium in the "external volume" of the molecular sieve and to increase the rate of passage of the solution through the molecular sieve.

Abstract: Novel cell lines produce monoclonal antibody to the light chain region of human factor XII. Three such cell lines, ATCC #HB-9703 through ATCC #HB-9704, are formed by fusing SP2/0-Ag14 myeloma cells with spleen cells from BALB/c AnSkh mice immunized with human factor XIIf. Biochemical and therapeutic uses of the monoclonal antibodies are provided.

Abstract: A method of recovering lactose from milk whey or cheese whey with a high yield, wherein the whey is concentrated, part of the lactose is crystallized, and the crystals are separated and dried; the mother liquor is purified by heating it to about 60.degree. to 70.degree. C. at a pH of about 5.8 to 7.0 and by removing the resultant precipitate by centrifugation; the purified mother liquor is fractionated chromatographically, using sulphonated polystyrene resin which is in sodium ion form and cross-linked by a 3-6% per weight divinylbenzene and which is even-grained, the flow rate is about 0.4 to 1.5 m.sup.3 /h, the temperature about 50.degree. to 75.degree. C., and the pH about 5.5 to 7; whereafter elution is carried out with water, and the following fractions are recovered: a protein fraction which may also contain salts, an intermediate fraction which is recirculated to the fractionating step, and a lactose fraction which is passed to the crystallization step.

Abstract: A channel protein has a Na.sup.+ /K.sup.+ selectivity of approximately 100 and capable of affecting Na.sup.+ membrane transport. Amiloride derivatives, and amiloride gel materials incorporating such derivatives, are useful in treating membrane transport, cellular volume and cellular pressure disorders and in isolating the channel protein. The channel protein is used in diagnostic assays and screening assays.

Abstract: Process for the selective extraction of metalloproteins from whey, by adsorption on a porous inorganic support in the form of particles, followed by elution of the metalloproteins thus absorbed by means of solutions, characterized in that the walls of the said particles are coated with a layer of aminated polysaccharides possessing acidic functional groups at the surface.

Abstract: The invention herein is directed to methods using Procion dyes to perform separations of interest in manipulating the NAD.sup.+ -independent ribotoxins. The methods are useful for preparing therapeutic agents contaning these ribotoxins of their A polypeptide components. This separation method has been applied in particular to preparing hybrid toxins containing ricin toxins, both of purifying the resulting products and also for separating the components intended to be used in the preparation of these end products. In addition, a novel ricin isotoxin prepared using the method of the invention is disclosed.

Abstract: Protein G from wild-type group G or group C streptococci is obtained by an extracting process using cyanogen bromide. The process gives yields ranging up to 60-fold better than the best prior art process known.

Abstract: A fluorescence-labeled Fab' is produced by causing a fluorescent substance to react with a Fab', dialyzing the resultant reaction solution, allowing the dialyzate to stand at rest thereby effecting reversion of unconjugated Fab' into F(ab').sub.2 and giving rise to a reaction solution containing a fluorescence-labeled Fab' and F(ab').sub.2 and collecting the fluorescence-labeled Fab' from the reaction solution.

Abstract: Proteins having therapeutic potential as both anticoagulants and as anti-inflammatory agents are disclosed. The present invention also discloses the use of lipocortins in reducing blood coagulation in warm-blooded animals.

Abstract: There are disclosed a recombinant interleukin-2 composition consisting essentially of water, recombinant interleukin-2, and optionally a polyol, said composition having a specific activity of at least about 120,000 units/mg and a process for preparing it by heating a suspension of the interleukin-2 at a specified temperature.